AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 23.86.
Share Price | ₹1,131.2 | Apr 26,2024 |
Market Cap | ₹66,274.1 Cr | |
Earnings-TTM | ₹2,777.9 Cr | TTM-Consolidated Results |
Price/Earnings | 23.86x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹66,274.1 Cr] as on Apr 26,2024
(/) Earnings [ ₹2,777.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 23.86x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 23.86 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 13.64x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2019 at 19.47x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
AUROBINDO PHARMA | 2,777.89 | 23.86 | 66,274.1 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8,998.63 | 40.11 | 360,920.0 |
CIPLA LTD | 3,744.03 | 30.39 | 113,794.0 |
DR REDDYS LABORATORIES LTD | 5,209.40 | 20.02 | 104,316.0 |
ZYDUS LIFESCIENCES LTD | 2,954.20 | 32.29 | 95,380.9 |
DIVIS LABORATORIES LTD | 1,382.97 | 77.27 | 106,860.0 |
MANKIND PHARMA LTD | 1,743.30 | 54.42 | 94,869.4 |
TORRENT PHARMACEUTICALS LTD | 1,494.00 | 60.95 | 91,057.0 |
LUPIN LTD | 1,809.74 | 40.69 | 73,642.4 |
ABBOTT INDIA LTD | 1,145.58 | 47.98 | 54,961.0 |
ALKEM LABORATORIES LTD | 1,574.66 | 37.22 | 58,604.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 20.02x |
Max industry PE | 77.27x |
Median industry PE | 40.11x |
Average industry PE | 42.29x |
You may also like the below Video Courses